SOURCE: Althea Technologies, Inc.

March 30, 2006 06:00 ET

Althea Technologies Announces the Appointment of Chris Duffy as VP of Operations and Roy Musil as VP of Quality and Regulatory Affairs

SAN DIEGO, CA -- (MARKET WIRE) -- March 30, 2006 -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today the appointment of two Vice Presidents to its Development and Regulatory areas. The appointment of Althea's experienced science and technology managers provides for additional leadership to support the company's continued expansion. Chris Duffy and Roy Musil bring more than 30 years of combined expertise in Pharmaceutical Development, Clinical Research, Process Development, Quality Control and Laboratory Management to the company's senior management.

Mr. Chris Duffy, appointed as Vice President of Operations, was formerly Althea's Executive Director of Analytical Services since 2000, where he directed the Testing Services area at Althea. His new role incorporates operational management responsibility for Althea's Contract Manufacturing for Active Pharmaceutical Ingredients. Mr. Duffy brings over 20 years of experience managing the operations of clinical research and manufacturing laboratories. From 1988 to 2000 he was a Senior Manager at The Immune Response Corporation where he managed the operation of a biosafety level III laboratory conducting Phase III clinical research.

Mr. Roy Musil was appointed Althea's Vice President of Quality and Regulatory Affairs. Prior to joining Althea in 2001, Mr. Musil served as a Technology Manager with GlaxoSmithKline's Biopharmaceutical Technology Group, Worldwide Supply Operations and holds a California State Board of Pharmacy exemption. In addition to his former management charter for Quality Assurance and Quality Control, Mr. Musil will now have the responsibility of Regulatory Affairs.

Co-President and Co-CEO of Althea, Dr. Magda Marquet, noted, "We are very proud to entrust additional senior management responsibilities to Chris Duffy and Roy Musil. Each of these managers has demonstrated their capabilities in very demanding roles at Althea and has the kind of cross-sectional expertise which is highly valuable in a company like ours where we support clients all along the pharmaceutical development path. Chris Duffy will lend additional management strength to our fastest growing business segment, and Roy Musil's new responsibility will allow us to address the quality and regulatory tasks which mirror our clients advance to commercial manufacturing."

Dr. François Ferré stated, "These accomplished senior managers will bolster our leadership as Althea continues to grow our core services and incorporate the latest technological advances into additional valuable industry services. Each of these gentlemen will play an important role in our continued success and have a reputation for solid performance among our clients, the industry and the regulatory agencies."

About Althea Technologies, Inc.

Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing and development services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea's services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, aseptic filling, and gene quantification using real-time PCR and gene expression analysis under GLP conditions. Additionally, Althea has introduced new services and technologies for the identification and understanding of gene signatures with innovative tools such as the company's proprietary eXpress Profiling™ technology. For more information, visit www.altheatech.com.

Contact Information

  • Contact:
    Althea Technologies, Inc.
    Alan Moore
    Executive Vice President and CBO
    (858) 882-0205
    Email Contact